<--- Back to Details
First PageDocument Content
Health / Monoclonal antibodies / Immunosuppressants / Structured Product Labeling / Adalimumab / Biologic License Application / Biologic / Pharmaceutical drug / Labeling theory / Medicine / Pharmacology / Food and Drug Administration
Date: 2009-12-03 09:58:12
Health
Monoclonal antibodies
Immunosuppressants
Structured Product Labeling
Adalimumab
Biologic License Application
Biologic
Pharmaceutical drug
Labeling theory
Medicine
Pharmacology
Food and Drug Administration

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993

Add to Reading List

Source URL: www.accessdata.fda.gov

Download Document from Source Website

File Size: 420,19 KB

Share Document on Facebook

Similar Documents

KULLANMA TALİMATI HUMIRA PEN (Adalimumab 40 mg/0.8 ml) kullanıma hazır enjeksiyon kalemi Derialtına enjeksiyon yoluyla uygulanır. • •

KULLANMA TALİMATI HUMIRA PEN (Adalimumab 40 mg/0.8 ml) kullanıma hazır enjeksiyon kalemi Derialtına enjeksiyon yoluyla uygulanır. • •

DocID: 1vrYV - View Document

アプリケーションノート No.20 カイコを用いた各種 FCGR の調製とヒト IgG との相互作用解析 【Syringe】240μM FCGR2A 【Cell】27.5μM adalimumab 【Buffer】PBS (pH7.4),

アプリケーションノート No.20 カイコを用いた各種 FCGR の調製とヒト IgG との相互作用解析 【Syringe】240μM FCGR2A 【Cell】27.5μM adalimumab 【Buffer】PBS (pH7.4),

DocID: 1uEy8 - View Document

EAP Reimbursement Criteria for Frequently Requested Drugs

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

Rabattverträge* zu HUMIRA® (Adalimumab) Wirtschaftliche Verordnung von HUMIRA® (Adalimumab) von AbbVie durch Rabattverträge zwischen AbbVie und folgenden Krankenkassen: actimonda Krankenkasse  BKK Gildemeister Seiden

Rabattverträge* zu HUMIRA® (Adalimumab) Wirtschaftliche Verordnung von HUMIRA® (Adalimumab) von AbbVie durch Rabattverträge zwischen AbbVie und folgenden Krankenkassen: actimonda Krankenkasse BKK Gildemeister Seiden

DocID: 1r9Jj - View Document

December 4, 2015  BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum 1. Teva, Takeda Form Generics Joint Venture in Japan Teva Pharmaceu

December 4, 2015 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum 1. Teva, Takeda Form Generics Joint Venture in Japan Teva Pharmaceu

DocID: 1qVa0 - View Document